Terumo Aortic Announces Completion of Enrolment of RelayPro US Pivotal Study

September 26, 2019

Terumo Aortic has announced the completion of enrolment of the RelayPro pivotal study in the United States. RelayPro is a low profile, next generation thoracic stent graft device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels.

RelayPro, having obtained CE Mark in 2018, utilises the same stent design, material and dual sheath technology already proven in Terumo Aortic's RelayPlus device, with the additional benefit of a 3 to 4 Fr reduction in outer profile.

The RelayPro aneurysm study is a prospective, multi-centre, non-blinded, non-randomised study of the RelayPro thoracic stent graft in patients with thoracic aortic aneurysms and penetrating atherosclerotic ulcers. The primary endpoint for safety is a composite of major adverse events; the primary endpoint for effectiveness is a composite of technical and clinical success.

One-hundred and ten patients have been enrolled in the study across sites in both the United States and Japan.

Dr Wilson Szeto (Cardiothoracic surgeon, University Medical Centre of Pennsylvania) Co-Principal Investigator, commented, "RelayPro's ability to land accurately combined with its low profile will allow me to successfully treat complex anatomy with precision."

This trial marks the first time both Bare Stent and Non-Bare Stent (NBS) configurations of RelayPro have been used in the United States. Dr Venkatesh Ramaiah (Vascular surgeon, HonorHealth Medical Group, Arizona) Co-Principal Investigator, stated, "One of the key benefits of RelayPro is being able to choose from a range of proximal configurations allowing me to tailor my device selection to meet the individual needs of each patient."

The completion of enrolment is an important milestone for Terumo Aortic as the company progresses towards the approval of RelayPro in the United States and Japan.

About Terumo Aortic

At Terumo Aortic, we understand that no two aortas are alike; our company's vision is to transform the treatment of aortic disease worldwide. We are 100% focused on the aorta, from the arch to the iliacs. With our comprehensive portfolio of surgical, endovascular and hybrid technologies and services, we help clinicians address their patients' unique challenges -- so no patient is left behind.

Notes to Editors

- Terumo Corporation of Japan, a global medical device company founded in 1921 currently has over 25,000 employees worldwide
- Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc in 2017
- Terumo Aortic has over 1,250 employees including 815 located in Glasgow, Scotland; 330 in Sunrise, Florida and the remaining within direct European markets.

Media Contact

Corporate Communication Dept., Terumo Corporation

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

Print
T
O
P